U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H17FN4O2
Molecular Weight 388.3944
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RSV-604

SMILES

FC1=CC=CC=C1NC(=O)N[C@H]2N=C(C3=CC=CC=C3)C4=C(NC2=O)C=CC=C4

InChI

InChIKey=MTPVBMVUENFFLL-HXUWFJFHSA-N
InChI=1S/C22H17FN4O2/c23-16-11-5-7-13-18(16)25-22(29)27-20-21(28)24-17-12-6-4-10-15(17)19(26-20)14-8-2-1-3-9-14/h1-13,20H,(H,24,28)(H2,25,27,29)/t20-/m1/s1

HIDE SMILES / InChI

Molecular Formula C22H17FN4O2
Molecular Weight 388.3944
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Respiratory syncytial virus nucleoprotein
Substance Class Chemical
Created
by admin
on Sat Dec 16 12:10:21 GMT 2023
Edited
by admin
on Sat Dec 16 12:10:21 GMT 2023
Record UNII
6NF9HI6D98
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RSV-604
Code English
1-(2-FLUOROPHENYL)-3-((3S)-2-OXO-5-PHENYL-1,3-DIHYDRO-1,4-BENZODIAZEPIN-3-YL)UREA
Systematic Name English
(S)-N-(2-FLUOROPHENYL)-N'-(2-OXO-5-PHENYL-2,3-DIHYDRO-1H-BENZO(E)(1,4)DIAZEPIN-3-YL)UREA
Systematic Name English
UREA, N-((3S)-2,3-DIHYDRO-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPIN-3-YL)-N'-(2-FLUOROPHENYL)-
Systematic Name English
RSV604
Code English
RSV 604
Code English
A-60444
Code English
Code System Code Type Description
EPA CompTox
DTXSID101125220
Created by admin on Sat Dec 16 12:10:21 GMT 2023 , Edited by admin on Sat Dec 16 12:10:21 GMT 2023
PRIMARY
CLINICAL_TRIALS.GOV
RSV-604
Created by admin on Sat Dec 16 12:10:21 GMT 2023 , Edited by admin on Sat Dec 16 12:10:21 GMT 2023
PRIMARY Primary Objectives:Pilot Study: A preliminary assessment of the exposure and safety of oral A-60444 in post-stem cell transplant patients with RSV infection.Main Study: To determine the antiviral effect of oral A-60444 versus placebo in post-stem cell transplant patients with RSV infection and to assess the safety of oral A-60444 in post-stem cell transplant patients with RSV infection.Secondary Objectives:To study the pharmacokinetics of A-60444 in the presence of concomitant medications such as immunosuppressants and antifungals, in post-stem cell transplant patients with RSV infection.
PUBCHEM
5279172
Created by admin on Sat Dec 16 12:10:21 GMT 2023 , Edited by admin on Sat Dec 16 12:10:21 GMT 2023
PRIMARY
DRUG BANK
DB15197
Created by admin on Sat Dec 16 12:10:21 GMT 2023 , Edited by admin on Sat Dec 16 12:10:21 GMT 2023
PRIMARY
FDA UNII
6NF9HI6D98
Created by admin on Sat Dec 16 12:10:21 GMT 2023 , Edited by admin on Sat Dec 16 12:10:21 GMT 2023
PRIMARY
SMS_ID
300000041381
Created by admin on Sat Dec 16 12:10:21 GMT 2023 , Edited by admin on Sat Dec 16 12:10:21 GMT 2023
PRIMARY
CAS
676128-63-5
Created by admin on Sat Dec 16 12:10:21 GMT 2023 , Edited by admin on Sat Dec 16 12:10:21 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY
Class: Antiviral, Benzodiazepinone, Phenylurea compound, Small molecule; Mechanism of Action: Nucleocapsid protein inhibitor, Virus replication inhibitor; Highest Development Phase: Discontinued for Respiratory syncytial virus infection; Most Recent Events: 16 Nov 2010 RSV 604 is still in active development, 02 Oct 2008 Preclinical trials in Respiratory syncytial virus infections (in infants) in United Kingdom (PO), 31 Oct 2006 Phase-I clinical trials in Respiratory syncytial virus infections in volunteers United Kingdom (IV)